
Takeda launches Orzeyful, first orexin agonist for narcolepsy type 1
Key Takeaways
- Orzeyful is the first therapy designed to address NT1’s core orexin deficit, potentially enabling qualitatively “normal” wakefulness compared with traditional stimulants and other symptomatic regimens.
- Pricing is set at $16,500 per 60 tablets regardless of strength, with payer engagement via pre-approval exchanges and a specialty-pharmacy-only channel intended to support contracting and Medicaid coverage.
Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.
Adults with narcolepsy type 1 can now be prescribed Orzeyful (oveporexton), an oral orexin receptor 2 agonist and the first drug designed to address the underlying orexin deficiency that drives the disease, Takeda announced last week in a
NT1, also called narcolepsy with cataplexy, is a rare, chronic neurological disease caused by a loss of orexin, a brain chemical that promotes wakefulness. It affects an estimated 120,000 people in the U.S., according to Takeda. Symptoms include excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), cognitive symptoms and disrupted nighttime sleep.
The disease is also costly for payers. Adults newly diagnosed with NT1 had total healthcare costs 5.5 times higher than matched controls in the first year after diagnosis, according to a Takeda-funded analysis
Emmanuel Mignot, M.D., Ph.D., a professor of sleep medicine at Stanford University and principal U.S. investigator for the Orzeyful phase 3 program, has spent decades studying orexin’s role in narcolepsy. He called the drug’s arrival “surreal.”
“The most important is that it is qualitatively and quantitatively different,” Mignot told Managed Healthcare Executive. “Suddenly they can experience being awake as normal people.”
Orzeyful pricing and access
The wholesale acquisition cost for Orzeyful is $16,500 per 60-tablet bottle, with the same price across all 3 strengths, a Takeda spokesperson told Managed Healthcare Executive.
“Its pricing reflects both the innovation and value the medicine brings to adults living with NT1, caregivers, the healthcare system and society,” the spokesperson said, adding that the company has engaged with payers through pre-approval information exchange.
Orzeyful is dispensed across the U.S. only through Accredo Specialty Pharmacy, part of Evernorth Health Services. Takeda said it chose the channel for its experience in narcolepsy, established payer contracts and Medicaid coverage in all 50 states and that it does not anticipate the arrangement will affect access. The company also offers a QuickStart program that may allow appropriate patients to begin treatment while coverage is being sorted out.
Payers will decide what diagnostic proof to require. Under standard diagnostic criteria (ICSD-3), excessive daytime sleepiness, a positive sleep study and cataplexy are enough to identify NT1, according to Takeda. Spinal fluid testing for low orexin is rarely done. Only about half of U.S. adults with NT1 are diagnosed and diagnosis takes an average of 10 years. Takeda said it is studying a blood-based orexin biomarker that could help.
On step therapy, Mignot said decisions should be left to patients and clinicians. “This is really an individual case,” he said. “The problem is simply that it should be to the doctor and patient to decide.” He added that trying another drug first rarely hurts, “although in the case of Orzeyful it may be harder to stop and have to go through rebound symptoms.”
Side effects and where Orzeyful fits
In pooled phase 3 studies, insomnia occurred in 58% of patients taking Orzeyful and urinary events in 63%. None of the insomnia cases led to discontinuation and two patients stopped treatment for urinary symptoms, according to Takeda. Prescribers can choose 1 mg or 2 mg twice daily. Orzeyful is contraindicated in patients taking strong CYP3A inhibitors, according to the
Orzeyful was studied as monotherapy and trial participants had to stop other narcolepsy drugs first. Mignot said he would start with patients “who are not doing optimally on their medication” and hopes, in most cases, to replace classic stimulants with it. For many patients, he said, sodium oxybate plus Orzeyful, or Orzeyful alone, will likely be the ideal approach, though “alone I don’t think it will be a magic pill.”
Long-term effects beyond about 3 years are not yet known, Mignot said.
Takeda is not exploring Orzeyful in other conditions, the company said. A second orexin agonist, TAK-360, is in phase 2 for narcolepsy type 2, idiopathic hypersomnia and NT1, with data expected by the end of March 2027.
When asked which outcomes would make the strongest case to payers, Mignot pointed to patients’ quality of life rather than any single measure. “Just the normalization of their symptoms and the ability to live a more normal life,” he said. “Mostly to gain back the freedom of being spontaneous, to not have to live a more restricted life.”
Related to this article








